openPR Logo
Press release

Fabry Disease Market show exponential growth by 2023

10-17-2017 07:56 AM CET | Advertising, Media Consulting, Marketing Research

Press release from: Transparency Market Research

/ PR Agency: Transparency Market Research

Fabry disease is an unusual, life-threatening situation with debilitating condition. Fabry disease is an uncommon X-linked inherited disorder. It is caused by the lack of the enzyme alpha galactosidase-A (a-GAL A). It is initiated by the absence of enzyme required to metabolize the lipids, fat-like substances like waxes, oils, and fatty acids. This disease is also known as alpha-galactosidase-A deficiency. Often there is a complete deficiency of a-Gal results in a severe form called the classic Fabry disease. This classic form mostly affects male. Symptoms of this disorder usually appear during childhood or adolescence in both male and female which includes pain that can be either full body or localized known as pricking sensation or numbness (acroparesthesia), gastro hyperactivity, burning sensation in hands, renal inefficiency, cardiac problem and cloudiness of cornea. The pain that is caused by the disease can be treated with anticonvulsants like phenytoin and carbamazepine. Gastric hyperactivity is treated by metoclopramide. Some patient may require dialysis or kidney replacement. However, restricting diet does not help to reduce lipid buildup in cells. The incidence of Fabry disease affects approximately 1 in 40,000 to 60,000 males. Occurrence of this disorder is less frequent in females.

Request Sample Copy of the Report@

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=9515 

 

Fabry disease market can be segmented on the basis of its treatment and geography. The type of treatment can be classified as Enzyme replacement therapy (ERT), Alternative therapies and Emergency treatment strategy. ERT has been available for the treatment of Fabry disease since 2001. U.S Food and Drug Administration has approved the ERT for the treatment of Fabry disease. ERT comforts the pain, decreases the lipid storage and preserves organ function in patients with this disorder. Alternative therapy involves palliative and supportive approach for the treatment of Fabry disease. Emergency treatment strategy involves administration of small molecule drugs which are very effective and have a quick response. 

The Fabry disease market presents an enormous opportunity in its treatment and cure. The driving factors those have been aiding the growth of The Global Fabry Disease Market. Firstly, there are provision for orphan drugs, diseases with restricted patient population, such as Fabry disease have limited approved drugs. Special benefits are given to this drugs like few years of market exclusivity, tax benefits for clinical testing and exclusion from prescription drug fees in order to recover the research and development expenses of the drug. 

Secondly, use of tools like ICD, it is a standard tool for diagnosis purposes. These codes are used for reimbursements by the private organizations or government insurers. The code for Fabry disease is E75.21 ICD-10-CM code. ICD-10 codes have been designed to provide superior specificity and better clinical details. ICD-10-CM codes are also expected to provide complete healthcare data, thus helping in the development of advanced clinical pathways and disease protocols. However, currently there is a lack of disease-modifying therapy in the Fabry disease market but there are lot of potential for the improvement in near future. 

Request TOC of the Report@

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=9515

 

Some of the key players in this market are Genzyme Corporation, Shire plc. Amicus Therapeutics. Inc., Synageva BioPharma Corp., JCR Pharmaceutical, ISU ABXIS Co. Ltd., Protalix BioTherapeutics, and Neuraltus Pharmaceuticals, Inc., Biosidus. 

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Fabry Disease Market show exponential growth by 2023 here

News-ID: 776003 • Views:

More Releases from Transparency Market Research

At a CAGR of 5.2%, Oral Solid Dosage Pharmaceutical Formulation Market is Projected to Reach USD 1.1 Billion by 2034 | TMR Research
At a CAGR of 5.2%, Oral Solid Dosage Pharmaceutical Formulation Market is Projec …
Oral solid dosage (OSD) forms are the most common and widely used pharmaceutical formulations, encompassing tablets, capsules, powders, and granules. These formulations are favored for their stability, ease of administration, and patient compliance. The global market for OSD pharmaceutical formulations is substantial, driven by advancements in drug delivery technologies, growing pharmaceutical industry, and increasing prevalence of chronic diseases requiring long-term medication. This article explores the current state and future prospects
Immersion Cooling Industry Set to Grow from USD 287.7 Million to USD 1.8 Billion by 2034
Immersion Cooling Industry Set to Grow from USD 287.7 Million to USD 1.8 Billion …
The global immersion cooling market (浸漬冷却市場) was valued at US$ 287.7 million in 2023. It is projected to advance at a compound annual growth rate (CAGR) of 17.9% from 2024 to 2034, reaching US$ 1.8 billion by the end of 2034. Download Sample Report Copy Here: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=83413&utm_source=OpenPR_Sandeep&utm_medium=OpenPR Analyst Viewpoint The increasing investment in data center infrastructure is a significant driver of the immersion cooling market. The surge in internet usage and data
Advanced Wind Turbine Blade Materials Market to Reach USD 9.8 Billion by 2034 with 6.3% CAGR
Advanced Wind Turbine Blade Materials Market to Reach USD 9.8 Billion by 2034 wi …
The global advanced wind turbine blade materials market (첨단 풍력 터빈 블레이드 재료 시장) was valued at US$ 5.0 billion in 2023. It is estimated to grow at a compound annual growth rate (CAGR) of 6.3% from 2024 to 2034, reaching US$ 9.8 billion by the end of 2034. Download Sample Report Copy Here: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86250&utm_source=OpenPR_Sandeep&utm_medium=OpenPR Analyst Viewpoint The reduction in fossil fuel dependency is a major factor driving the development of the
Non-Muscle Invasive Bladder Cancer Market Size is Anticipated to Grow at a CAGR of 21.4% by 2034 | TMR Study
Non-Muscle Invasive Bladder Cancer Market Size is Anticipated to Grow at a CAGR …
Non-muscle invasive bladder cancer (NMIBC) represents a significant portion of bladder cancer cases, characterized by cancerous cells confined to the inner layers of the bladder wall. NMIBC includes stages Ta, T1, and carcinoma in situ (CIS). The management of NMIBC focuses on tumor removal, recurrence prevention, and progression to muscle-invasive stages. The global market for NMIBC treatments is expanding, driven by advancements in diagnostic techniques, emerging treatment modalities, and increasing

All 5 Releases


More Releases for Fabry

Fabry Disease Market Expected to Rise Steadily throughout 2026
Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency. It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme. The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme. Fabry disease is known to cause variety of systemic symptoms and complications, one of
Fabry Disease - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Fabry Disease - Pipeline Review, H2 201 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fabry Disease - Pipeline Review, H2 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape. Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called
Fabry Disease Market | Analysis & Key Trends 2023
Fabry disease is an unusual, life-threatening situation with debilitating condition. Fabry disease is an uncommon X-linked inherited disorder. It is caused by the lack of the enzyme alpha galactosidase-A (a-GAL A). It is initiated by the absence of enzyme required to metabolize the lipids, fat-like substances like waxes, oils, and fatty acids. This disease is also known as alpha-galactosidase-A deficiency. Often there is a complete deficiency of a-Gal results in
Fabry Disease - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Fabry Disease - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fabry Disease - Pipeline Review, H1 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape. Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called
Fabry Disease Market Intelligence Report Offers Growth Prospects
Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency. It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme. The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme. Fabry disease is known to cause variety of systemic symptoms and complications, one of
Worldwide Fabry Disease Market Report 2016-2026
Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency. It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme. The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme. Fabry disease is known to cause variety of systemic symptoms and complications, one of